APLP2

Across TCGA pan-cancer cohorts, APLP2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of APLP2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where APLP2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types APLP2 is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

HNSC, PDAC, and CCRCC are the cancer types where APLP2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in APLP2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.474	<.001	11	view →
PDAC	Female	II,III,IV	+0.466	<.001	6	view →
CCRCC	Male	All	−0.276	<.001	6	view →
LSCC	Male	II,III,IV	−0.307	<.001	5	view →
LUAD	Female	III,IV	+0.383	.015	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

APLP2–HNSC

Open the HNSC breakdown →